Stryker Corporation $SYK Shares Sold by Bernard Wealth Management Corp.

Bernard Wealth Management Corp. cut its holdings in shares of Stryker Corporation (NYSE:SYK) by 16.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 379 shares of the medical technology company’s stock after selling 77 shares during the period. Bernard Wealth Management Corp.’s holdings in Stryker were worth $150,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Sachetta LLC lifted its stake in Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 27 shares during the last quarter. Goodman Advisory Group LLC acquired a new stake in shares of Stryker during the first quarter valued at approximately $32,000. Ridgewood Investments LLC raised its holdings in shares of Stryker by 48.4% during the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after acquiring an additional 30 shares during the period. Ransom Advisory Ltd acquired a new stake in shares of Stryker during the first quarter valued at approximately $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Stryker during the first quarter valued at approximately $40,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Down 1.5%

Stryker stock opened at $364.77 on Friday. The firm has a market cap of $139.46 billion, a PE ratio of 48.31, a P/E/G ratio of 2.67 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm’s 50 day moving average price is $380.25 and its two-hundred day moving average price is $378.75. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s payout ratio is currently 44.50%.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of recent analyst reports. Evercore ISI cut their price target on shares of Stryker from $418.00 to $410.00 and set an “outperform” rating on the stock in a report on Tuesday. Truist Financial set a $415.00 price target on shares of Stryker and gave the company a “hold” rating in a report on Monday, August 4th. Redburn Partners set a $420.00 price target on shares of Stryker in a report on Thursday, September 18th. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a report on Thursday, September 18th. Finally, Wells Fargo & Company boosted their price target on shares of Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $430.10.

Insider Activity at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.